{{medical}}
{{Infobox drug
| drug_name         = 
| IUPAC_name        = 
| image             = Bis-choline tetrathiomolybdate (molecular structure).png
| width = 250
| alt               = 
| caption           =

<!-- Clinical data -->
| tradename         =Decuprate 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = Investigational
| routes_of_administration =

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         =

<!-- Identifiers -->
| CAS_number_Ref    = {{cascite|changed|??}}
| CAS_number        = 649749-10-0
| ATCvet            = 
| ATC_prefix        = none
| ATC_suffix        = 
| PubChem           = 18442052
| DrugBank          = DB05088
| ChemSpiderID      = 19906891
| UNII              = 91U3TGV99T

<!-- Chemical data -->
| synonyms = 四硫代钼酸双胆碱<BR>双胆碱四硫代钼酸盐<BR>ATN-224、WTX101
| C=10 | H=28 | Mo=1 | N=2 | O=2 | S=4
| molecular_weight  = 432.542 g/mol
| StdInChI = 1S/2C5H14NO.Mo.4S/c2*1-6(2,3)4-5-7;;;;;/h2*7H,4-5H2,1-3H3;;;;;/q2*+1;;;;2*-1
| StdInChIKey = NEYVHGQOGHJAAD-UHFFFAOYSA-N
|  smiles = OCC[N+](C)(C)C.[S-][Mo]([S-])(=S)=S.C[N+](C)(C)CCO
}}

'''四硫代钼酸胆碱'''（又称'''胆碱四硫代钼酸盐'''，商品名为'''Decuprate'''），是[[胆碱|胆碱]]所形成的[[硫代钼酸盐|硫代钼酸盐]]（TTM, MoS<sub>4</sub><sup>2−</sup>）。作为[[威尔逊氏病|威尔逊氏病]]的治疗方法，这是一种身体不能调节铜的罕见且潜在的致命疾病。威尔逊病是一种常染色体[[隐性遗传性疾病|隐性遗传性疾病]]，有严重的[[肝|肝]]、[[神经|神经]]或[[精神症状|精神症状]]的表现。若未经诊断和未经治疗，该疾病可能致命。据估计，全世界每3万人中约有1人患有威尔逊氏病，相当于[[欧盟|欧盟]]约有1万5千人而[[美国|美国]]约有1万1千人。<ref>{{cite journal|pmid=17276780|year=2007|author1=Ala|first1=A|title=Wilson's disease|journal=The Lancet|volume=369|issue=9559|pages=397–408|last2=Walker|first2=A. P.|last3=Ashkan|first3=K|last4=Dooley|first4=J. S.|last5=Schilsky|first5=M. L.|doi=10.1016/S0140-6736(07)60196-2}}</ref>

已经在患有各种癌症的患者的临床试验中评估了四硫代钼酸胆碱，<ref name="Berenson">{{cite journal|vauthors=Berenson JR, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, Mazar AP, Reich SD|year=2006|title=Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients with Advanced Hematologic Malignancies Presentation at the Amer Soc Hematol 2006 Annual Meeting|journal=Blood|volume=108|at=Abstract 2593}}</ref><ref name="Lin">{{cite journal|pmid=21816640|pmc=3227793|year=2013|author1=Lin|first1=J|title=A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer|journal=Urologic Oncology: Seminars and Original Investigations|volume=31|issue=5|pages=581–8|last2=Zahurak|first2=M|last3=Beer|first3=T. M.|last4=Ryan|first4=C. J.|last5=Wilding|first5=G|last6=Mathew|first6=P|last7=Morris|first7=M|last8=Callahan|first8=J. A.|last9=Gordon|first9=G|last10=Reich|first10=S. D.|last11=Carducci|first11=M. A.|last12=Antonarakis|first12=E. S.|doi=10.1016/j.urolonc.2011.04.009}}</ref><ref name="Lowndes">{{cite journal|pmid=19010871|year=2008|author1=Lowndes|first1=S. A.|title=Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors|journal=Clinical Cancer Research|volume=14|issue=22|pages=7526–34|last2=Adams|first2=A|last3=Timms|first3=A|last4=Fisher|first4=N|last5=Smythe|first5=J|last6=Watt|first6=S. M.|last7=Joel|first7=S|last8=Donate|first8=F|last9=Hayward|first9=C|last10=Reich|first10=S|last11=Middleton|first11=M|last12=Mazar|first12=A|last13=Harris|first13=A. L.|doi=10.1158/1078-0432.CCR-08-0315}}</ref>并在美国和欧盟成为了[[孤儿药|孤儿药]]（即罕见药），作为威尔逊氏病的潜在治疗方法。<ref>[http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/03/WC500139536.pdf Public summary of opinion on orphan designation: Choline tetrathiomolybdate for the treatment of Wilson's disease], EMA/COMP/795268/2012, ATN-224, 18 February 2013.</ref><ref>[http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=346511 Orphan Drug Designations and Approvals: choline tetrathiomolybdate], U.S. Food and Drug Administration, 25 August 2011</ref>

四硫代钼酸胆碱是威尔逊治疗学公司的代号为WTX101的威尔逊氏病临床开发中的去铜疗法用药，该公司由[[HealthCap|HealthCap]]于2012年成立。

==参考文献==
{{reflist}}

[[category:季铵盐|category:季铵盐]]
[[category:硫代钼酸盐|category:硫代钼酸盐]]